Article Versions Notes

Huang L, Li J, Yang J, Zhang X, Zhang M, He J, Zhang G, Li W, Wang H, Li J, et al. Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. Cells. 2022; 11(24):4085. https://doi.org/10.3390/cells11244085

Huang, Lefu, Jingjing Li, Junfang Yang, Xian Zhang, Min Zhang, Jiujiang He, Gailing Zhang, Wenqian Li, Hui Wang, Jianqiang Li, and et al. 2022. "Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma" Cells 11, no. 24: 4085. https://doi.org/10.3390/cells11244085

Huang, L., Li, J., Yang, J., Zhang, X., Zhang, M., He, J., Zhang, G., Li, W., Wang, H., Li, J., & Lu, P. (2022). Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. Cells, 11(24), 4085. https://doi.org/10.3390/cells11244085